Lynch Syndrome Tumor Panel, IHC with Interpretation
Also known as: MSH2, MMR=mismatch repair, MLH1, Hereditary Nonpolyposis Colorectal Cancer (HNPCC), MSH6
Use
Immunohistochemistry (IHC) based tumor screening test for Lynch syndrome by evaluating mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) to identify mismatch repair deficiency suggestive of Lynch syndrome; serves as a prognostic and predictive screening tool to determine if germline genetic testing may be indicated.
Special Instructions
Available only with interpretation; performed using formalin‑fixed, paraffin‑embedded tissue block or 10 unstained positively charged slides as acceptable specimens.
Limitations
This is not a genetic test and does not detect germline variants; absence or presence of protein staining is a screening tool and may not definitively diagnose Lynch syndrome; further testing (genetic, BRAF, MLH1 promoter methylation) may be needed.
Methodology
Immunoassay (IHC)
Biomarkers
Result Turnaround Time
2-3 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Paraffin Embedded Tissue Block or 10 unstained positively charged slides
Collection Instructions
1 Formalin‑fixed, paraffin‑embedded tissue block; 10 unstained, positively charged slides are also acceptable
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Indefinite |
| Refrigerated | Indefinite |
| Frozen | Unacceptable |